Planning multi-arm screening studies within the context of a drug development program

Screening trials are small trials used to decide whether an intervention is sufficiently promising to warrant a large confirmatory trial. Previous literature examined the situation where treatments are tested sequentially until one is considered sufficiently promising to take forward to a confirmatory trial. An important consideration for sponsors of clinical trials is how screening trials should be planned to maximize the efficiency of the drug development process. It has been found previously that small screening trials are generally the most efficient. In this paper we consider the design of screening trials in which multiple new treatments are tested simultaneously. We derive analytic formulae for the expected number of patients until a successful treatment is found, and propose methodology to search for the optimal number of treatments, and optimal sample size per treatment. We compare designs in which only the best treatment proceeds to a confirmatory trial and designs in which multiple treatments may proceed to a multi-arm confirmatory trial. We find that inclusion of a large number of treatments in the screening trial is optimal when only one treatment can proceed, and a smaller number of treatments is optimal when more than one can proceed. The designs we investigate are compared on a real-life set of screening designs. Copyright © 2013 John Wiley & Sons, Ltd.

[1]  Frank Bretz,et al.  Comparison of Methods for the Computation of Multivariate t Probabilities , 2002 .

[2]  Thomas Jaki,et al.  Optimal design of multi‐arm multi‐stage trials , 2012, Statistics in medicine.

[3]  Richard Simon,et al.  Two-stage selection and testing designs for comparative clinical trials , 1988 .

[4]  Patrick Royston,et al.  Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer , 2003, Statistics in medicine.

[5]  P F Thall,et al.  A two-stage design for choosing among several experimental treatments and a control in clinical trials. , 1989, Biometrics.

[6]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[7]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[8]  KyungMann Kim Group Sequential Methods with Applications to Clinical Trials , 2001 .

[9]  Gernot Wassmer,et al.  On Sample Size Determination in Multi-Armed Confirmatory Adaptive Designs , 2011, Journal of biopharmaceutical statistics.

[10]  Martin Posch,et al.  Testing and estimation in flexible group sequential designs with adaptive treatment selection , 2005, Statistics in medicine.

[11]  J. Wason,et al.  Optimal multistage designs for randomised clinical trials with continuous outcomes , 2011, Statistics in medicine.

[12]  J. Whitehead,et al.  A generalized Dunnett Test for Multi-arm Multi-stage Clinical Studies with Treatment Selection , 2012 .

[13]  Frank Bretz,et al.  Adaptive designs for confirmatory clinical trials , 2009, Statistics in medicine.

[14]  Tim Friede,et al.  A group‐sequential design for clinical trials with treatment selection , 2008, Statistics in medicine.

[15]  Steven A. Julious,et al.  Sample size of 12 per group rule of thumb for a pilot study , 2005 .

[16]  John A. Nelder,et al.  A Simplex Method for Function Minimization , 1965, Comput. J..

[17]  M. Hoelscher,et al.  Innovative trial designs are practical solutions for improving the treatment of tuberculosis. , 2012, The Journal of infectious diseases.

[18]  J Whitehead,et al.  Designing phase II studies in the context of a programme of clinical research. , 1985, Biometrics.

[19]  J Whitehead,et al.  Sample sizes for phase II and phase III clinical trials: an integrated approach. , 1986, Statistics in medicine.

[20]  Tim Friede,et al.  A Comparison of Methods for Adaptive Treatment Selection , 2008, Biometrical journal. Biometrische Zeitschrift.

[21]  M. Parmar,et al.  Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial , 2009, Trials.

[22]  Nigel Stallard,et al.  Optimal sample sizes for phase II clinical trials and pilot studies , 2012, Statistics in medicine.

[23]  D. Bloch,et al.  Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. , 2005, Addiction.

[24]  J Whitehead,et al.  Group sequential clinical trials with triangular continuation regions. , 1983, Biometrics.